126 related articles for article (PubMed ID: 2108854)
1. A new short infusion dosage regimen of recombinant tissue plasminogen activator in patients with venous thromboembolic disease.
Levine MN; Weitz J; Turpie AG; Andrew M; Cruickshank M; Hirsh J
Chest; 1990 Apr; 97(4 Suppl):168S-171S. PubMed ID: 2108854
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism.
Levine M; Hirsh J; Weitz J; Cruickshank M; Neemeh J; Turpie AG; Gent M
Chest; 1990 Dec; 98(6):1473-9. PubMed ID: 2123152
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of bolus administration of alteplase in massive pulmonary embolism.
Diehl JL; Meyer G; Igual J; Collignon MA; Giselbrecht M; Even P; Sors H
Am J Cardiol; 1992 Dec; 70(18):1477-80. PubMed ID: 1442621
[TBL] [Abstract][Full Text] [Related]
4. Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group.
Agnelli G; Iorio A; Parise P; Goldhaber SZ; Levine MN
Blood Coagul Fibrinolysis; 1997 Jun; 8(4):216-22. PubMed ID: 9199818
[TBL] [Abstract][Full Text] [Related]
5. Bolus thrombolysis in venous thromboembolism.
Agnelli G; Parise P
Chest; 1992 Apr; 101(4 Suppl):172S-182S. PubMed ID: 1555482
[TBL] [Abstract][Full Text] [Related]
6. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomized trial. The Bolus Alteplase Pulmonary Embolism Group.
Goldhaber SZ; Agnelli G; Levine MN
Chest; 1994 Sep; 106(3):718-24. PubMed ID: 8082347
[TBL] [Abstract][Full Text] [Related]
7. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial.
Goldhaber SZ; Kessler CM; Heit JA; Elliott CG; Friedenberg WR; Heiselman DE; Wilson DB; Parker JA; Bennett D; Feldstein ML
J Am Coll Cardiol; 1992 Jul; 20(1):24-30. PubMed ID: 1607532
[TBL] [Abstract][Full Text] [Related]
8. Bolus, front-loaded, and accelerated thrombolytic infusions for myocardial infarction and pulmonary embolism.
Levine MN
Chest; 1991 Apr; 99(4 Suppl):128S-134S. PubMed ID: 2009809
[TBL] [Abstract][Full Text] [Related]
9. [rt-PA in extracardiac thromboembolic vascular occlusions].
Cortellaro M; Cofrancesco E; Polli EE
Ann Ital Med Int; 1990; 5(1):61-9. PubMed ID: 2119673
[TBL] [Abstract][Full Text] [Related]
10. Thrombolysis in venous thromboembolism. An international perspective.
Goldhaber SZ
Chest; 1990 Apr; 97(4 Suppl):176S-181S. PubMed ID: 2108856
[TBL] [Abstract][Full Text] [Related]
11. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
[TBL] [Abstract][Full Text] [Related]
12. Lower dosage of recombinant tissue-type plasminogen activator (rt-PA) in the treatment of acute pulmonary embolism: a systematic review and meta-analysis.
Zhang Z; Zhai ZG; Liang LR; Liu FF; Yang YH; Wang C
Thromb Res; 2014 Mar; 133(3):357-63. PubMed ID: 24412030
[TBL] [Abstract][Full Text] [Related]
13. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator.
Jang IK; Gold HK; Leinbach RC; Fallon JT; Collen D
Circ Res; 1990 Dec; 67(6):1552-61. PubMed ID: 2123135
[TBL] [Abstract][Full Text] [Related]
14. New developments in thrombolytic therapy.
Collen D; Gold HK
Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
[TBL] [Abstract][Full Text] [Related]
15. Fibrinolytic therapy of deep vein thrombosis with continuous intravenous infusion of a recombinant tissue plasminogen activator.
Zimmerman R; Gürsoy A; Horn A; Harenberg J; Diehm C; Kübler W
Semin Thromb Hemost; 1991 Jan; 17(1):48-54. PubMed ID: 1904629
[TBL] [Abstract][Full Text] [Related]
16. Coagulation alterations due to local fibrinolytic therapy with recombinant tissue-type plasminogen activator (rt-PA) in patients with peripheral arterial occlusive disease.
Rauber K; Heidinger KS; Kemkes-Matthes B
Cardiovasc Intervent Radiol; 1997; 20(3):169-73. PubMed ID: 9134838
[TBL] [Abstract][Full Text] [Related]
17. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
Collen D; Stassen JM; Yasuda T; Refino C; Paoni N; Keyt B; Roskams T; Guerrero JL; Lijnen HR; Gold HK
Thromb Haemost; 1994 Jul; 72(1):98-104. PubMed ID: 7974384
[TBL] [Abstract][Full Text] [Related]
18. [Repeated local thrombolysis in a patient with axillary and subclavian vein injury and thrombosis].
Sárník S; Hofírek I
Vnitr Lek; 2009 Nov; 55(11):1102-4. PubMed ID: 20017444
[TBL] [Abstract][Full Text] [Related]
19. Recombinant tissue-type plasminogen activator in canine embolic pulmonary hypertension. Effects of bolus versus short-term administration on dynamics of thrombolysis and on pulmonary vascular pressure-flow characteristics.
Prewitt RM; Shiffman F; Greenberg D; Cook R; Ducas J
Circulation; 1989 Apr; 79(4):929-38. PubMed ID: 2494007
[TBL] [Abstract][Full Text] [Related]
20. [Successful lysis of a septic thrombosis of the superior vena cava using recombinant tissue-plasminogen activator].
Schranz D; Haugwitz D; Zimmer B; Schumacher R
Klin Padiatr; 1991; 203(5):363-5. PubMed ID: 1942943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
